INTERNATIONAL PATENT: SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD, 深圳信立泰药业股份有限公司 FILES APPLICATION FOR "MEDICAL USE OF COMBINATION OF ENDOTHELIN A (ETA) RECEPTOR ANTAGONIST AND SGLT-2 INHIBITOR"

Posted On: 2025-12-29

GENEVA, Dec. 29 -- SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD (Zone A, 4F, 289 Digitland, 2 Hongliu Road, Futian DistrictShenzhen, Guangdong 518017), 深圳信立泰药业股份有限公司 (中国广东省深圳市福田区福保街道福保社区红柳道2号289数字半岛4层A区) filed a patent application (PCT/CN2025/102236) for "MEDICAL USE OF COMBINATION OF ENDOTHELIN A (ETA) RECEPTOR ANTAGONIST AND SGLT-2 INHIBITOR" on Jun 20, 2025. With publication no. WO/2025/261457, the details related to the patent application was publish...

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

INTERNATIONAL PATENT: SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD, 深圳信立泰药业股份有限公司 FILES APPLICATION FOR "MEDICAL USE OF COMBINATION OF ENDOTHELIN A (ETA) RECEPTOR ANTAGONIST AND SGLT-2 INHIBITOR"